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The relation between thyroid function and depression has long been recognized. Patients with thyroid disorders are more prone
to develop depressive symptoms and conversely depression may be accompanied by various subtle thyroid abnormalities. Tradi-
tionally, the most commonly documented abnormalities are elevated T4 levels, low T3, elevated rT3, a blunted TSH response to
TRH,positiveantithyroidantibodies,andelevatedCSFTRHconcentrations. Inaddition,thyroidhormonesupplementsappearto
accelerateandenhancetheclinicalresponsetoantidepressantdrugs.However,themechanismsunderlyingtheinteractionbetween
thyroidfunctionanddepressionremaintobefurtherclariﬁed.Recently,advancesinbiochemical,genetic,andneuroimagingﬁelds
have provided new insights into the thyroid-depression relationship.
1.Introduction
The association between thyroid function and psychiatric
disorders particularly mood disorders has long been recog-
nized. Historically, this association has been described more
than 200 years ago. Parry in 1825 reported an increased inci-
dence of “nervous aﬀectations” in thyroid disorders. Gull in
1873 showed the relation between myxedema and psychosis
that was conﬁrmed in 1888 by the Committee of the Clinical
Society. Later, Asher in 1949 coined the term “myxedema
madness” to describe the mental state of subjects with hypo-
thyroidism [1].
Today, it is well recognized that disturbances in thyroid
function may signiﬁcantly aﬀect mental status including
emotion and cognition. Both excess and insuﬃcient thyroid
hormones can cause mood abnormalities including depres-
sion that is generally reversible with adequate thyroid treat-
ment. On the other hand, depression can be accompanied by
subtle thyroid dysfunction. Overt thyroid disease is rare in
depression.Oneto4%of patientswithaﬀectivedisordersare
found to have overt hypothyroidism while subclinical hypo-
thyroidism occurs in 4% to 40% of these patients [2]. Fur-
thermore, thyroid hormones are reported by many authors
to be an eﬀective adjunct treatment for depression.
In this paper, we will present an overview of thyroid hor-
mone metabolism in the brain, reexamine the diﬀerent ob-
servations and clinical studies assessing the relationship
between thyroid and depression, and shed light on the ad-
vances in neuroimaging approaches in this ﬁeld. Under-
standingthelinkbetweenbothdisorderswillguideclinicians
to appropriately interpret thyroid function tests in depres-
sion,betterunderstandthepathophysiologyofbothdiseases,
and try to identify the subjects who will beneﬁt the most
from thyroid supplementation.
2.LiteratureSearch
A PubMed search was performed through the English liter-
ature from 1969 to present using the keywords: “accelera-
tion,” “antidepressant treatments,” “augmentation,” “brain,”
“depression,” “hyperthyroidism,” “hypothyroidism,” and
“mood disorder.”
3. OverviewofThyroidHormoneMetabolismin
the Brain
The hypothalamic-pituitary-thyroid axis (HPT) is a complex
interplay between several factors: thyroid hormones, deiodi-
naseenzymes,transporterproteins,andreceptors.Anunder-
standingoftheinteractionsofthesefactorsmaycontributeto2 Journal of Thyroid Research
better elucidate the pathophysiology of psychiatric disorders
as well as the response to psychiatric treatment.
The secretion of thyroid hormones is regulated by pitu-
itary thyrotropin (TSH) which itself is stimulated by hypo-
thalamic thyrotropin-releasing hormone (TRH) and down-
regulated by serum thyroid hormones. Twenty percent of tri-
iodothyronine (T3) in the cerebral cortex is secreted directly
by the thyroid while 80% is derived from local conversion
of thyroxine (T4) by deiodination [3, 4]. Most of the T4
enter the brain via a number of transporters including trans-
thyretin (TTR), a thyroid hormone transport protein syn-
thesized by the choroid plexus and secreted into the cere-
brospinal ﬂuid [5, 6]. Deiodination occurs intracellularly
mainly in glial cells and T4 must enter these cells through
specialized plasma membrane carrier proteins including
organic anion transporter polypeptide 1 (OATP1C1) and
monocarboxylase transporter 8 (MCT8). The former prefer-
entiallytransportsT4andrT3whilethelatterismorespeciﬁc
for T3 transport [7]. In the glial cells, T4 is converted to T3
by the deiodinase enzyme type 2 (D2) while it is inactivated
to 3,3 ,5 -triiodothyronine (rT3) in the neuronal cells by the
deiodinase enzyme type 3 (D3). The latter also deiodinates
T3 into inactive T2. The actions of T3 are mediated by bind-
ing to thyroid hormone nuclear receptors (THRs). In the
adult brain, THR-α is most highly expressed and constitutes
70–80% of THR distribution [8].
Thus, the HPT axis includes complex pathways and im-
pairment in its components has been linked in some studies
to behavioral changes as will be further pointed out.
4. NeuropsychiatricManifestationsof
Thyroid Disorders
Primary thyroid disorders including both hypothyroidism
andhyperthyroidismmaybeaccompaniedbyvariousneuro-
psychiatricmanifestationsrangingfrommilddepressionand
anxiety to overt psychosis.
Dysphoria, anxiety, irritability, emotional lability, and
impairment in concentration constitute the classical neuro-
psychiatric symptoms occurring in hyperthyroidism or thy-
rotoxicosis. However, elderly patients may present in a state
mimicking a depressive disorder with apathy, lethargy, and
pseudodementia [9]. Anxiety disorders have been found to
occur in approximately 60% of hyperthyroid patients while
depressive disorders occurred in 31 to 69% [10, 11].
On the other hand, hypothyroid patients frequently
demonstrate features of depression, cognitive dysfunction,
apathy, and psychomotor slowing. In severe forms of hypo-
thyroidism, clinical symptoms may mimic that of melan-
cholic depression and dementia [12]. However, there is less
evidence on the association of subclinical hypothyroidism
with cognitive dysfunction and aﬀective disorders particu-
larly depression although recently, a prevalence of 63.5%
of depressive symptoms was reported in an Italian popula-
tion with subclinical hypothyroidism. Nevertheless, therapy
with levothyroxine alone was not suﬃcient to induce a
total remission of depressive symptoms in this population
[13]. Furthermore, Bauer et al. showed that TSH levels in
hypothyroidism correlated with disease severity [14]a n d
Joﬀe and Levitt found a disparity in depressive symptoms
manifestations and severity among patients with a low-nor-
mal TSH versus those with a high-normal TSH. However,
in the latter study no diﬀerence in treatment outcome was
observed between the two groups [15]. In patients treated
with T4, psychological symptoms may persist even when
they achieve a euthyroid state [16]. Impaired psychological
wellbeing in these subjects may be related to the occurrence
of genetic polymorphisms in the D2 gene [17]a sw e l la st h e
OATPC1 encoding gene [18].
According to the American Association of Clinical Endo-
crinologists, “The diagnosis of subclinical or clinical hypo-
thyroidism must be considered in every patient with dep-
ression” [19]. Indeed, among the various neuropsychiatric
manifestations of thyroid disorders, depression remains the
most common [20].
5. Thyroid Status in Patients with Depression
Several thyroid abnormalities have been associated with
mood disorders particularly depression. However, the vast
majorityofpatientswithdepressiondonothavebiochemical
evidence of thyroid dysfunction [21, 22]. When thyroid ab-
normalities exist, they consist mainly of elevated T4 levels,
low T3, elevated rT3, blunted TSH response to TRH, positive
antithyroid antibodies, and elevated cerebrospinal ﬂuid
(CSF) TRH concentrations. A state of brain hypothyroidism
inthesettingofsystemiceuthyroidism[23–25]hasbeensug-
gested. This could result from a defect in the thyroid hor-
monereceptor[26],orinthethyroidhormonetransportand
uptake into the brain and neuronal cells [7, 27]. Mice with
receptor-mediatedhypothyroidismcausedbyaheterozygous
mutation in the THRα-1 have shown increased depressive
behavior responsive to continuous T3 administration [26].
Furthermore, lower levels of CSF TTR have been reported
in patients with depression compared to controls [28–30]
resulting in a state of “brain hypothyroidism” with, nonethe-
less, normal peripheral thyroid hormones [28]. Mutations
in MCT8 have also been recognized to cause isolated brain
hypothyroidism by blocking T3 transport into neurons [8,
31].
6. PeripheralThyroidHormoneConcentrations
6.1. Thyroxine (T4). Studies examining total and free plas-
matic T4 levels in patients with depression have shown
inconsistent results. Serum T4 levels in the upper range of
normalorslightlyhigherhavebeenreportedindepressedpa-
tients as compared to healthy or psychiatric controls. These
levelshavebeenfoundtoregressaftersuccessfultreatmentof
depression [32].
One mechanism explaining the increase in T4 seen in
depression is the activation of hypothalamic TRH producing
neurons and subsequent increase in thyroid function sec-
ondary to the rise in cortisol associated with depression [19,
24,33].Inaddition,ithasbeenshownthatelevatedserumT4
levels fall after successful treatment of depression. A direct
eﬀect of antidepressants on the TRH neuron has been de-
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This suggests that the decrease in T4 levels with initiation of
antidepressants could be secondary to a direct eﬀect on TRH
neuron and thus to a reduced stimulation of the thyroid axis.
Recently, the Caerphilly Prospective Study examined the
link between thyroid function and minor psychiatric mor-
bidity among 2269 middle-aged men. A weak positive asso-
ciation between total T4 and chronic psychiatric morbidity
was observed after 12.3 years of followup. However, this was
consistentwithchanceafteradjustmentsweredoneforsocial
class, alcohol, and smoking behaviors. On the other hand,
meta-analyses of seven studies showed TSH to be negatively
correlated with depression and total T4 to be positively re-
lated to a depressed mood [35].
6.2.Triiodothyronine(T3)and3,3 ,5 -Triiodothyronine(rT3).
In patients with depression and no other illnesses, a “low T3
syndrome” has been described [36]. In one study [37] ,an o r -
mal daily production of T3 was reported among unmedi-
cated and moderately depressed patients. The combination
ofincreasedT4yetnormalT3productionsupportsthehypo-
thesis of a reduced deiodination of T4 into T3 as seen in the
euthyroid sick syndrome [37]. An elevated rT3 was also re-
ported in association with unipolar depression [38]a sd e -
monstrated by Linnoila et al., and Kirkegaard and Faber
found as well high rT3 levels in endogenous depression that
normalized after electroconvulsive therapy [39]. It has been
hypothesized that depression leads to inhibition of the D2
enzyme responsible for conversion of T4 into T3 due to the
i n c r e a s ei nc o r t i s o ll e v e l s[ 40]. This favors the production of
rT3 by D3 enzyme. In addition, elevated levels of rT3 were
found in CSF of patients with unipolar depression [41].
7. AntithyroidAntibodies
A prevalence of up to 20% of elevated titers of antithyroid
antibodies has been documented in depressed patients in
several reports compared to a 5–10% prevalence in the gen-
eral population [42–45]. However, this should be viewed
with caution since these reports either lacked a controlgroup
[42, 43, 45] or showed no signiﬁcant diﬀerence between the
groupwithanaﬀectivedisorder andthecontrolgroupwitha
nonaﬀectivepsychiatricdisorder[44].Furthermore,whether
this link may have any clinical signiﬁcance remains unclear
since it was most often accompanied by normal serum TSH
concentrations [42, 43]. In addition, Fountoulakis et al.
found higher thyroid binding inhibitory immunoglobulins
(TBII) in depressed patients suggesting the presence of an
autoimmune process involving the thyroid gland in depres-
sed patients [46].
8. Blunted TSH Response andAbnormal
DiurnalRhythm
Depression has been linked to various endogenous circadian
rhythms abnormalities such as diurnal mood variation, ab-
normalities in core body temperature, cortisol secretion, and
sleep-wake cycle [47]. In addition to these circadian dysfunc-
tions, depression has been linked to an abnormal diurnal
TSH rhythm as well. An absent TSH nocturnal surge [48]
has been noted in depression and a lower basal TSH has
been reported in major depression as opposed to nonmajor
depression [49]. Furthermore, a blunted TSH response to
TRH was reported in about 25–30% of depressed subjects
compared to healthy ones [50–54]. One preeminent hypoth-
esis to explain the above ﬁnding is that chronic TRH hyper-
secretion associated with depression leads to downregulation
of pituitary TRH receptors [24, 53, 55, 56]. In support to
this hypothesis are reports of elevated CSF concentrations of
TRH in depressed patients [57, 58].
The prolonged release of TRH in depression may be seen
as a compensatory response to the decreased 5HT activity in
an attempt to normalize 5HT function and maintain normal
levelsofthyroidhormones[59].Analternativeexplanationis
that the blunted TSH response may be induced by the hyper-
cortisolism associated with depression or the elevated thy-
roid hormone levels mediated by adrenergic mechanisms
[60, 61].
In addition, TRH has been postulated in early studies to
have an antidepressant eﬀect.
Administration of TRH at a dose of 500μgp a r e n t e r a l l y
to unipolar depressed women led to a signiﬁcant improve-
ment in depression ratings [50, 51]. Furthermore, TRH-R1
knockout mice showed increased anxiety and depression-
like behavior thus supporting a role for endogenous TRH in
mood regulation [62]. The extent to which the endogenous
TRH system is involved in mood regulation and the underly-
ing implicated mechanisms remain to be deﬁned.
9. Thyroid Hormone Supplementation
inDepression
Thyroid hormones have been used as an adjunct to antide-
pressant therapy since the late 1960s to accelerate clinical
response to antidepressants (acceleration) and to potentiate
clinical response in non-responders to antidepressants (aug-
mentation).
An acceleration of antidepressant eﬀect by T3 has been
initiallyshownmorethan30yearsagoinseveralreports[63–
66].Ameta-analysisoftheseearlydouble-blindplacebocon-
trolled trials concluded that T3 was eﬀective in accelerating
the clinical response to tricyclic antidepressants in patients
with nonrefractory depression. The eﬀects of T3 acceleration
appeared to be more remarkable as the percentage of women
in a trial increased therefore suggesting that women might
beneﬁt more than men from T3 supplementation [67]. In
addition, several reports examined the role of T3 as an aug-
mentation strategy to antidepressants in refractory depres-
sion. The majority involved the use of tricyclic antidepres-
sants and supported the role for T3 in managing refractory
depression [68]. More recently, studies assessing the newer
and more tolerable antidepressant agents, the selective sero-
tonin reuptake inhibitors (SSRIs) in combination with T3
have yielded confounding results. A meta-analysis of these
studies concluded that simultaneous initiation of T3 and
SSRI is not signiﬁcantly more likely to accelerate or enhance
the clinical response in depressed patients compared to SSRI
monotherapy. However, the authors suggested that T3 and
SSRI cotherapy may be eﬀective in a subset of depressed4 Journal of Thyroid Research
patients including those with atypical depression, or those
with functional D1 gene polymorphism [69]. As previously
described,D1hasakeyroleinT4toT3conversion.Inastudy
by Cooper-Kazaz et al. patients with C785T polymorphism
inD1genehadabetterresponsetoT3augmentationtherapy.
Therefore, depressed patients with genetically determined
lower T4 to T3 conversion could therefore derive more
beneﬁt from thyroid hormone augmentation therapy [70].
Fewer studies assessed the eﬃcacy of T4 in the treatment
of aﬀective disorders. Joﬀe and Singer found a signiﬁcantly
higher response to tricyclic antidepressants with T3 (53%)
compared to T4 (19%) [71]. However, use of T4 in sup-
raphysiological doses to treatment-resistant unipolar and
bipolar depression was eﬀective in approximately 50% of
patientsasreportedbyBaumgartnerinareviewofeightopen
clinical trials (N = 78) [72]. Surprisingly, T4 in high doses
was well tolerated even in patients treated for up to 51
months. However, in healthy subjects, supraphysiological T4
doses were less well tolerated due to higher increments in
thyroid hormones after supplementation [73]. A possible
explanation would be a greater inactivation of T4 to rT3 in
depressed patients compared to healthy subjects [74].
Clearly, further research is needed to ascertain whether
thyroid hormone supplementation may eﬀectively accelerate
and potentiate therapeutic response to antidepressant drugs.
In addition, the role of genetic variations in deiodinase en-
zymes in the response to antidepressive therapy merits fur-
ther investigation.
10. Effect of Depression Treatment on
Thyroid Status
Normalization of pretreatment thyroid function tests mainly
T4 levels with remission of depression has been reported
[75, 76]. Whether this is related to clinical recovery or merely
ar e s u l to fad i r e c te ﬀect of antidepressants remains to be
determined.
Both tricyclic antidepressants [77] and SSRIs [78]a p p e a r
to enhance the activity of D2 resulting in an increased
conversionofT4intoactiveT3inthebrain.T3wassuggested
to enhance neurotransmission in the central noradrenergic
pathways [79] and deﬁciency in catecholamines has been
raised as a possible mechanism in depression [80]. Addition-
ally, it has been shown that anti-depressants with variable
mechanisms of action have diﬀerent eﬀects on thyroid in-
dices [81]. Further studies are therefore required to better
elucidate this complex interaction between the HPT axis and
the neurotransmitter system.
11. Associationof Depressionwith
PostpartumThyroid Disease
The association of postpartum depression with postpartum
thyroiditis or with positive thyroid antibodies is still not well
deﬁned. Early studies noted a minor association between
thyroid dysfunction and postnatal depression [82]. More
recently, a higher frequency of mild to moderate depression
w a so b s e r v e di np o s t p a r t u mf e m a l es u b j e c t sw i t hp o s i t i v e
antithyroid antibodies regardless of thyroid function [83–
85]. However, an attempt to decrease the incidence of post-
partum depression in thyroid antibody positive women with
daily administration of thyroxine for 18 weeks postpartum
was unsuccessful [86].
12. NeuroimaginginThyroid and
Mood Disorders
A few studies have been performed to assess the changes in
cerebral perfusion and metabolism in patients with hypothy-
roidism particularly those with Hashimoto’s thyroiditis or
status post-thyroidectomy for thyroid carcinoma.
Some have reported diﬀuse global hypoperfusion [87–
89] while others demonstrated decreased regional cerebral
blood ﬂow [90–92]. Furthermore, variable ﬁndings regard-
ingrestorationofbloodﬂowwithtreatmenthavebeendocu-
mented. While some demonstrated at least partial normal-
ization of cerebral blood ﬂow [14, 87, 89] others found per-
sistent hypoperfusion with restoration of the euthyroid state
[90–92].
Theinconsistencyintheaboveﬁndingscanbeaccounted
forby the variability in the degree of hypothyroidism and the
diﬀerences in the etiology and duration of the disease in the
various studied populations.
Studies assessing cerebral blood ﬂow and metabolism in
depression are more numerous. The most widely replicated
ﬁnding from these studies is hypoperfusion in anterior corti-
cal structures [93, 94] that was reversible after psychotherapy
and pharmacotherapy[95–97].In addition to frontal hypop-
erfusion, increased perfusion has been observed in various
limbic regions most notably the amygdala [93].
In a study comparing cerebral blood ﬂow in hypothy-
roidism and major depression, hypothyroid patients exhib-
ited hypoperfusion in posterior aspects of the brain in con-
trast to an anterior cerebral hypoperfusion in depressed pa-
tients. Furthermore, normalization of perfusion abnormali-
ties in patients with depression after treatment was observed
w h i l en oc h a n g ei nc e r e b r a lb l o o dﬂ o ww a sn o t e di nh y p o -
thyroidism. This implies that behavioral symptoms in dep-
r e s s i o nm a yb em e d i a t e db yd i ﬀerent neural circuits from
that seen in hypothyroidism [92].
13. Conclusion
Clinical investigators have long recognized the link between
thyroid and depression. While patients with hypothyroidism
commonly manifest features of depression, hyperthyroidism
presents with a wider spectrum of neuropsychiatric symp-
toms including both depression and anxiety. On the other
hand,mostofthepatientswithprimarydepressionhavenor-
mal thyroid function. The mechanisms underlying the inter-
actionbetweenthyroidfunctionanddepressionremaintobe
clariﬁed and a causal relationship between the two cannot be
established yet. A possible role for thyroid autoimmunity in
the pathogenesis of depression can be elucidated. Screening
patients presenting with depression for thyroid dysfunction
seems reasonable particularly those with refractory symp-
toms. However, the use of thyroid hormones as an adjunctJournal of Thyroid Research 5
therapy to antidepressants in the absence of subclinical or
clinical hypothyroidism should be further investigated. In
addition, specifying a particular patient population that
might beneﬁt from this combination as determined by indi-
vidual genetic variants should be addressed. The continuing
researchinthebiochemical,genetic,andneuroimagingﬁelds
seems most promising in providing a deeper understanding
of the thyroid-depression interactions.
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